AbbVie prevails in Sandoz IPR challenge of HUMIRA® formulation patent
Clients AbbVie Inc.
Jones Day served as lead counsel and successfully defended AbbVie in connection with an inter partes review (IPR) petition filed by Sandoz, Inc. against U.S. Patent No. 8,802,100, which is related to formulations for AbbVie's antibody adalimumab, marketed as HUMIRA®. Sandoz is developing a biosimilar version of HUMIRA®, which is the top selling drug in the world. Following the filing of the Patent Owner's Preliminary Response by AbbVie, the PTAB denied institution of Sandoz's IPR petition with regard to all of the challenged claims.
Sandoz Inc. v. AbbVie Biotechnology Ltd., IPR2017-01823 (PTAB)